Clear Liquids, Safer Procedures

To the Editor We read with interest the OCULUS randomized clinical trial by Ahmad and colleagues that evaluated the effects of continuing vs withholding glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (GLP-1/GIP RAs) before upper endoscopy. As the first such trial to our knowledge, it addressed a gap in evidence regarding periprocedural management of these agents, which has previously been guided mainly by observational data and expert opinion.